Moreover, amisulpride as a carrier combined with mesalazine, which is an anti-inflammatory drug, subsequently synthesizes to a new compound that could treat colonic diseases, and this new compound has an improved ability to decrease the levels of inducible nitric oxide synthase, cyclooxygenase-2, IL-1β, IL-6, and TNF-α [29]. The gene discussed is IL6; the disease is colonic disorder.